Research ExplorerPublicationsPhase I clinical and magnetic resonance imaging study of the...

Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041).

Links

  • van Laarhoven
  • Walter Fiedler
  • Walter Fiedler
  • Ingrid M E Desar
  • van Asten
  • J A Jack
  • Sandrine Marréaud
  • Denis Lacombe
  • Anne-Sophie Govaerts
  • Jan Bogaerts
  • Peter Lasch
  • Johanna N H Timmer-Bonte
  • Antonio Lambiase
  • Claudio Bordignon
  • Cornelis J A Punt
  • Arend Heerschap
  • van Herpen
  • M L Carla

Related Research units

Abstract

This phase I trial investigating the vascular targeting agent NGR-hTNF aimed to determine the (a) dose-limiting toxicities, (b) maximum tolerated dose (MTD), (c) pharmacokinetics and pharmacodynamics, (d) vascular response by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), and (e) preliminary clinical activity in solid tumors.

Bibliographical data

Original languageGerman
Article number4
ISSN1078-0432
Publication statusPublished - 2010
pubmed 20145168